Advances in Clinical Research on Prevention and Treatment of Diabetic Nephropathy by Jingfang of Promoting Blood Circulation and Removing Blood Stasis

Aim and Objective: To evaluate the efficacy and safety of Chinese herbal medicines for promoting blood circulation and removing blood stasis (PBCRBSM) in preventing deep venous thrombosis (DVT) after total hip arthroplasty (THA). Materials and Methods: The Databases were searched for studies comparing the preventive abilities of PBCRBSM and Western medicine, such as low molecular weight heparin (LMWH), rivaroxaban, and aspirin, as well as for randomized controlled trials on DVT after THA. Data were analyzed using RevMan 5.3 software. Results: A total of 3254 randomized controlled trials were included, including 1630 cases in the experimental group and 1624 cases in the control group. Meta-analysis showed that compared with Western medicine, PBCRBSM reduced the incidence of DVT (OR=0.38, 95% CI [0.30, 0.48], P < 0.001); prolonged activated partial thromboplastin time (APTT) (SMD=0.44, 95% CI [0.35, 0.53], P < 0.001); reduced D-dimer (SMD=-0.75, 95% CI [-0.84，-0.65], P < 0.001), FIB (SMD=-0.61, 95% CI [-0.72, -0.50], P < 0.001), blood viscosity (P<0.01), circumference difference in lower extremities (P<0.01), venous blood flow velocity (SMD=0.97, 95% CI [0.77, 1.16], P < 0.001), and drainage volume (SMD=-1.53, 95% CI [-1.71, -1.35], P < 0.001); and reduced adverse reactions (OR = 0.32, 95% CI [0.19, 0.56], P < 0.001). There was no significant difference in prolonging prothrombin time (PT) between traditional Chinese medicine and Western medicine (SMD = 0.07, 95% CI [-0.0.01). 3, 0.16], P > 0.05. Conclusion: PBCRBSM is an effective method for preventing DVT after THA and has fewer adverse effects.

Download Full-text

Effect of regulating qi and invigorate blood circulation method on hemorrheology in rats with acute blood stasis syndrome and its network pharmacology research

IOP Conference Series Earth and Environmental Science ◽

10.1088/1755-1315/632/5/052070 ◽

2021 ◽

Vol 632 ◽

pp. 052070

Author(s):

Ying Mei ◽

Yong Feng ◽

Zhaohui Zi ◽

Xiang Pu

Keyword(s):

Blood Circulation ◽

Blood Stasis ◽

Blood Stasis Syndrome ◽

Network Pharmacology ◽

Circulation Method

Download Full-text

Comparison of mechanisms and efficacies of five formulas for improving blood circulation and removing blood stasis

Digital Chinese Medicine ◽

10.1016/j.dcmed.2021.06.007 ◽

2021 ◽

Vol 4 (2) ◽

pp. 144-158

Author(s):

L.I. Jinxia ◽

Z.H.O.U. Xiaoqing ◽

Z.H.E.N.G. Caixing ◽

L.A.I. Lina ◽

L.I. Ling

Keyword(s):

Blood Circulation ◽

Blood Stasis

Download Full-text

Efficacy and safety of Suxiao Jiuxin Pill in the treatment of stable angina (Qi stagnation and blood stasis syndrome): study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial

Trials ◽

10.1186/s13063-021-05448-6 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Xiaofen Ruan ◽

Yiping Li ◽

Yuanlong Sun ◽

Meijun Jia ◽

Xiaowen Xu ◽

...

Keyword(s):

Clinical Trial ◽

Clinical Research ◽

Stable Angina ◽

Conventional Therapy ◽

Blood Stasis ◽

Chronic Stable Angina ◽

Blood Stasis Syndrome ◽

Double Blind ◽

Double Blind Placebo ◽

Qi Stagnation

Abstract Background Coronary heart disease (CHD) has become one of the biggest health problems in the world. Stable angina is a common clinical type of CHD with poor prognosis and high mortality. Although there are various interventions for stable angina, none of them can significantly reduce mortality. Both basic and clinical research have shown that Suxiao Jiuxin Pill (SJP) can relieve the symptoms of angina pectoris and improve the clinical efficacy, but there is a lack of high-quality clinical research to provide research-based evidence. We design a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of SJP for stable angina. Methods/design This is a prospective, randomized, double-blind, placebo-controlled, and multicenter trial. The trial will enroll 324 participants with chronic stable angina (Qi Stagnation and Blood Stasis syndrome). All participants will have received the conventional therapy of chronic stable angina. Participants will be randomized into two groups, conventional therapy plus SJP group and conventional therapy plus placebo group. Eligible participants will receive either SJP or placebo (five pills administered orally, three times daily) in addition to conventional treatment for 24 weeks. The primary outcomes are the symptom improvement rate of angina from baseline to 4 weeks after inclusion and major adverse cardiovascular events (MACE). The secondary outcomes are angina classification (CCS), improvement of traditional Chinese medicine (TCM) syndromes, Seattle Angina Scale score, the dosage of emergency drugs and the stopping rate, and electrocardiogram (EKG) efficacy. Adverse events will be monitored throughout the trial. Discussion Integrated traditional Chinese and Western Medicine is commonly used for angina in China. This study will evaluate the clinical effectiveness and safety of SJP for angina. The results of the trial will provide high-level clinical research-based evidence for the application of SJP instable angina. Trial registration This study protocol was registered on 14 March 2019. The registration number is ChiCTR1900021876 on the Chinese Clinical Trial Registry.

Download Full-text

Application Research of Promoting Blood Circulation and Removing Blood-Stasis in Internal Medicine Clinic of Traditional Chinese Medicine

10.47939/mh.v1i2.100 ◽

2020 ◽

Keyword(s):

Internal Medicine ◽

Chinese Medicine ◽

Traditional Chinese Medicine ◽

Blood Circulation ◽

Blood Stasis ◽

Application Research ◽

Medicine Clinic ◽

Internal Medicine Clinic

Download Full-text

The therapeutic effect and mechanism of Qishen Yiqi dripping pills on cardiovascular and cerebrovascular diseases and diabetic complications

Current Molecular Pharmacology ◽

10.2174/1874467214666210811153610 ◽

2021 ◽

Vol 14 ◽

Author(s):

Chunlai Zhao ◽

Wenjia Wang ◽

Kaijing Yan ◽

He Sun ◽

Jihong Han ◽

...

Keyword(s):

Coronary Heart Disease ◽

Diabetic Nephropathy ◽

Heart Disease ◽

Ischemic Stroke ◽

Diabetic Complications ◽

Blood Stasis ◽

Blood Stasis Syndrome ◽

Syndrome Differentiation ◽

Therapeutic Effects ◽

The Common

: The alterations in vascular homeostasis is deeply involved in the development of numerous diseases, such as coronary heart disease, stroke, and diabetic complications. Changes in blood flow and endothelial permeability caused by vascular dysfunction are the common mechanisms for these three types of diseases. The disorders of glucose and lipid metabolism can result in changes of the energy production patterns in endothelium and surrounding cells which may consequently cause local energy metabolic disorders, oxidative stress and inflammatory responses. Traditional Chinese medicine (TCM) follows the principle of the “treatment by the syndrome differentiation”. TCM considers of that coronary heart disease, stroke and diabetes complications all as the type of “Qi deficiency and Blood stasis” syndrome, which mainly happens to the vascular system. Therefore, the common pathogenesis of these three types of diseases suggests the treatment strategy by TCM should be in a close manner and named as “treating different diseases by the same treatment”. Qishen Yiqi dripping pills is a modern Chinese herbal medicine which has been widely used for treatment of patients with coronary heart disease characterized as “Qi deficiency and blood stasis” in China. Recently, many clinical reports have demonstrated the potent therapeutic effects of Qishen Yiqi dripping pills on ischemic stroke and diabetic nephropathy. Based on these reports, we will summarize the clinical applications of Qishen Yiqi dripping pills on coronary heart disease, ischemic stroke and diabetic nephropathy, including the involved mechanisms with basic researches.

Download Full-text